vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $207.8M, roughly 1.4× IDEAYA Biosciences, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 57.4%, a 39.0% gap on every dollar of revenue.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
ACAD vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $207.8M |
| Net Profit | $273.6M | $119.2M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 52.2% |
| Net Margin | 96.3% | 57.4% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | 330.1% |
| EPS (diluted) | $1.61 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | $207.8M | ||
| Q2 25 | $264.6M | — | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | $0 | ||
| Q2 24 | $242.0M | $0 | ||
| Q1 24 | $205.8M | $0 |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $119.2M | ||
| Q2 25 | $26.7M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $-51.8M | ||
| Q2 24 | $33.4M | $-52.8M | ||
| Q1 24 | $16.6M | $-39.6M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 52.2% | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | 57.4% | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | $1.33 | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $-0.60 | ||
| Q2 24 | $0.20 | $-0.68 | ||
| Q1 24 | $0.10 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.1B |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | $786.9M | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | $920.0M | ||
| Q2 24 | $177.1M | $701.7M | ||
| Q1 24 | $204.7M | $698.8M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | $1.1B | ||
| Q2 25 | $822.4M | — | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | $1.2B | ||
| Q2 24 | $516.7M | $931.7M | ||
| Q1 24 | $464.0M | $935.3M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | $1.2B | ||
| Q2 24 | $914.1M | $973.7M | ||
| Q1 24 | $855.1M | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $142.2M | ||
| Q2 25 | $64.0M | — | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | $-49.2M | ||
| Q2 24 | $25.0M | $-32.9M | ||
| Q1 24 | $29.1M | $-43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 1.19× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
IDYA
Segment breakdown not available.
